Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease

Author:

Hung Adriana M.12ORCID,Assimon Victoria A.3,Chen Hua-Chang14ORCID,Yu Zhihong14,Vlasschaert Caitlyn5,Triozzi Jefferson L.2ORCID,Chan Helen3,Wheless Lee6ORCID,Wilson Otis12,Shah Shailja C.7ORCID,Mack Taralynn18ORCID,Thompson Trevor2ORCID,Matheny Michael E.149ORCID,Chandrasekar Saranya3ORCID,Mozaffari Sahar V.3ORCID,Chung Cecilia P.10,Tsao Philip1112ORCID,Susztak Katalin13ORCID,Siew Edward D.12ORCID,Estrada Karol3,Gaziano J. Michael1415,Graham Robert R.3ORCID,Tao Ran14ORCID,Hoek Maarten3ORCID,Robinson-Cohen Cassianne2,Green Eric M.3ORCID,Bick Alexander G.814ORCID,

Affiliation:

1. Nashville VA Medical Center, VA Tennessee Valley Healthcare System, Nashville, Tennessee

2. Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

3. Maze Therapeutics, South San Francisco, California

4. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

5. Department of Medicine, Queen's University, Kingston, Ontario, Canada

6. Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee

7. VA San Diego Healthcare System and UC San Diego Health, La Jolla, California

8. Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

9. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee

10. Department of Rheumatology, Vanderbilt University Medical Center, Nashville, Tennessee

11. VA Palo Alto Health Care System, Palo Alto, California

12. Department of Medicine, Stanford University School of Medicine, Stanford, California

13. Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania

14. VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts

15. Department of Medicine, Brigham and Women's Hospital and Harvard School of Medicine, Boston, Massachusetts

Abstract

Significance Statement African Americans are at increased risk of CKD in part due to high-risk (HR) variants in the apolipoprotein L1 (APOL1) gene, termed G1/G2. A different APOL1 variant, p.N264K, reduced the risk of CKD and ESKD among carriers of APOL1 HR variants to levels comparable with individuals with APOL1 low-risk variants in an analysis of 121,492 participants of African ancestry from the Million Veteran Program (MVP). Functional genetic studies in cell models showed that APOL1 p.N264K blocked APOL1 pore-forming function and ion channel conduction and reduced toxicity of APOL1 HR mutations. Pharmacologic inhibitors that mimic this mutation blocking APOL1-mediated pore formation may be able to prevent and/or treat APOL1-associated kidney disease. Background African Americans are at increased risk for nondiabetic CKD in part due to HR variants in the APOL1 gene. Methods We tested whether a different APOL1 variant, p.N264K, modified the association between APOL1 HR genotypes (two copies of G1/G2) and CKD in a cross-sectional analysis of 121,492 participants of African ancestry from the MVP. We replicated our findings in the Vanderbilt University Biobank (n=14,386) and National Institutes of Health All of Us (n=14,704). Primary outcome was CKD and secondary outcome was ESKD among nondiabetic patients. Primary analysis compared APOL1 HR genotypes with and without p.N264K. Secondary analyses included APOL1 low-risk genotypes and tested for interaction. In MVP, we performed sequential logistic regression models adjusting for demographics, comorbidities, medications, and ten principal components of ancestry. Functional genomic studies expressed APOL1 HR variants with and without APOL1 p.N264K in cell models. Results In the MVP cohort, 15,604 (12.8%) had two APOL1 HR variants, of which 582 (0.5%) also had APOL1 p.N264K. In MVP, 18,831 (15%) had CKD, 4177 (3%) had ESKD, and 34% had diabetes. MVP APOL1 HR, without p.N264K, was associated with increased odds of CKD (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.60 to 1.85) and ESKD (OR, 3.94; 95% CI, 3.52 to 4.41). In MVP, APOL1 p.N264K mitigated the renal risk of APOL1 HR, in CKD (OR, 0.43; 95% CI, 0.28 to 0.65) and ESKD (OR, 0.19; CI 0.07 to 0.51). In the replication cohorts meta-analysis, APOL1 p.N264K mitigated the renal risk of APOL1 HR in CKD (OR, 0.40; 95% CI, 0.18 to 0.92) and ESKD (OR, 0.19; 95% CI, 0.05 to 0.79). In the mechanistic studies, APOL1 p.N264K blocked APOL1 pore-forming function and ion channel conduction and reduced toxicity of APOL1 HR variants. Conclusions APOL1 p.N264K is associated with reduced risk of CKD and ESKD among carriers of APOL1 HR to levels comparable with individuals with APOL1 low-risk genotypes.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Nephrology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3